Carmen Bozic Sells 1,020 Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) Stock

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) CMO Carmen Bozic sold 1,020 shares of the company’s stock in a transaction that occurred on Thursday, June 18th. The shares were sold at an average price of $462.17, for a total value of $471,413.40. Following the completion of the transaction, the chief marketing officer directly owned 15,933 shares in the company, valued at $7,363,754.61. This trade represents a 6.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Carmen Bozic also recently made the following trade(s):

• On Monday, June 15th, Carmen Bozic sold 4,062 shares of Vertex Pharmaceuticals stock. The stock was sold at an average price of $450.00, for a total value of $1,827,900.00.
• On Friday, June 5th, Carmen Bozic sold 1,745 shares of Vertex Pharmaceuticals stock. The stock was sold at an average price of $450.00, for a total value of $785,250.00.
• On Tuesday, May 12th, Carmen Bozic sold 6,988 shares of Vertex Pharmaceuticals stock. The shares were sold at an average price of $450.00, for a total value of $3,144,600.00.

Vertex Pharmaceuticals Price Performance

Vertex Pharmaceuticals stock opened at $475.20 on Thursday. Vertex Pharmaceuticals Incorporated has a one year low of $362.50 and a one year high of $507.92. The business’s fifty day moving average is $440.46 and its 200 day moving average is $453.72. The stock has a market capitalization of $120.61 billion, a PE ratio of 28.19, a price-to-earnings-growth ratio of 2.00 and a beta of 0.30.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Monday, May 4th. The pharmaceutical company reported $4.47 earnings per share for the quarter, topping analysts’ consensus estimates of $4.24 by $0.23. The business had revenue of $2.99 billion during the quarter, compared to analyst estimates of $2.99 billion. Vertex Pharmaceuticals had a return on equity of 23.86% and a net margin of 35.51%.Vertex Pharmaceuticals’s revenue was up 8.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $4.06 EPS. As a group, sell-side analysts expect that Vertex Pharmaceuticals Incorporated will post 17.02 EPS for the current fiscal year.

Trending Headlines about Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Vertex received an upgrade-driven boost from commentary highlighting povetacicept as a potential new growth driver, reinforcing optimism that the company’s pipeline can support earnings beyond its cystic fibrosis franchise. Article Title
• Positive Sentiment: New pediatric data for CASGEVY showed strong clinical benefits and a consistent safety profile in children, supporting Vertex’s regulatory and commercial outlook for its CRISPR-based therapy. Article Title
• Positive Sentiment: Analyst sentiment remains constructive, with multiple firms reiterating bullish views and price targets above the current share price, suggesting continued institutional confidence in Vertex’s longer-term growth story. Article Title

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Motiv8 Investments LLC bought a new position in Vertex Pharmaceuticals in the 4th quarter worth $26,000. Swiss RE Ltd. bought a new stake in Vertex Pharmaceuticals during the fourth quarter valued at about $28,000. Eagle Bay Advisors LLC bought a new stake in Vertex Pharmaceuticals during the fourth quarter valued at about $29,000. IMG Wealth Management Inc. increased its position in Vertex Pharmaceuticals by 277.8% in the fourth quarter. IMG Wealth Management Inc. now owns 68 shares of the pharmaceutical company’s stock worth $31,000 after buying an additional 50 shares in the last quarter. Finally, Colonial Trust Co SC raised its stake in shares of Vertex Pharmaceuticals by 118.8% in the third quarter. Colonial Trust Co SC now owns 70 shares of the pharmaceutical company’s stock worth $27,000 after buying an additional 38 shares during the period. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Canaccord Genuity Group dropped their target price on shares of Vertex Pharmaceuticals from $437.00 to $436.00 and set a “hold” rating on the stock in a report on Tuesday, May 5th. HC Wainwright boosted their target price on shares of Vertex Pharmaceuticals from $591.00 to $641.00 and gave the company a “buy” rating in a research note on Tuesday, March 10th. Wall Street Zen upgraded Vertex Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, June 20th. Morgan Stanley lifted their price objective on Vertex Pharmaceuticals from $612.00 to $616.00 and gave the stock an “overweight” rating in a report on Tuesday, May 5th. Finally, Royal Bank Of Canada upped their price objective on Vertex Pharmaceuticals from $541.00 to $543.00 and gave the company an “outperform” rating in a research report on Tuesday, May 5th. Twenty-two investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, Vertex Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $555.91.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.